Age-related Macular Degeneration (AMD) Therapeutics Market Generated Opportunities, Future Scope 2023-2030

 

Age-related Macular Degeneration (AMD) is a progressive eye condition that affects the macula, the central portion of the retina responsible for sharp central vision. It is the leading cause of vision loss in individuals over the age of 50 in developed countries. AMD can be classified into two main types: dry AMD and wet AMD.

Dry AMD, also known as non-neovascular AMD, is the more common form and is characterized by the presence of drusen, which are yellow deposits that accumulate beneath the retina. Dry AMD progresses slowly and usually does not cause severe vision loss. However, in some cases, it can progress to advanced dry AMD or geographic atrophy, where the light-sensitive cells in the macula gradually break down, leading to significant vision loss.

Wet AMD, also known as neovascular AMD, is less common but more severe. It occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, causing damage to the macula. Wet AMD can lead to rapid and severe vision loss if left untreated.

Therapeutic approaches for AMD aim to slow down disease progression, prevent vision loss, and, if possible, restore lost vision. Here are some of the key treatment options for AMD:

1. Anti-vascular endothelial growth factor (anti-VEGF) therapy: This is the primary treatment for wet AMD. Anti-VEGF drugs, such as ranibizumab, bevacizumab, and aflibercept, are injected into the eye to block the activity of VEGF, a protein responsible for the growth of abnormal blood vessels. By inhibiting new blood vessel formation and reducing leakage, anti-VEGF therapy can help preserve vision and prevent further damage.
2. Photodynamic therapy (PDT): PDT involves injecting a light-sensitive drug, such as verteporfin, into the bloodstream. The drug selectively accumulates in abnormal blood vessels in the retina. A low-power laser is then applied to the affected area, activating the drug and causing damage to the abnormal vessels while sparing healthy tissue. PDT is less commonly used now due to the widespread adoption of anti-VEGF therapy.
3. Laser photocoagulation: This treatment uses a high-energy laser to seal off leaking blood vessels in the macula. It is primarily used for a specific type of wet AMD called extrafoveal or juxtafoveal CNV (choroidal neovascularization) where the abnormal vessels are away from the central vision area. Laser photocoagulation is less commonly used due to the potential risk of damaging healthy retinal tissue.
4. Implantable mini telescopes: For individuals with advanced dry AMD or geographic atrophy in both eyes, implantable mini telescopes can be an option. These small telescopic devices are surgically implanted into one eye, enlarging the central vision and improving visual acuity. However, they also reduce peripheral vision and require extensive visual rehabilitation.
5. Nutritional supplements: Certain vitamins and minerals, such as vitamin C, vitamin E, zinc, copper, and antioxidants (lutein and zeaxanthin), have been studied for their potential role in slowing down the progression of dry AMD. The Age-Related Eye Disease Study (AREDS) and AREDS2 have shown that specific combinations of these supplements can reduce the risk of advanced AMD in certain individuals.

It's important to note that AMD is a complex condition, and the choice of treatment depends on the type and stage of the disease, as well as individual patient factors. Regular eye examinations and early detection are crucial for effective management of AMD. Consulting with an ophthalmologist or retina specialist is essential to determine the most appropriate therapeutic approach for each individual case.